The ARP & the Rheumatology Research Foundation are key partners in advancing rheumatology. Learn how they support care, training & research on their anniversaries.
The early initiation of biologic disease-modifying anti-rheumatic drugs (DMARDs) may reduce the overall disease burden in patients with polyarticular juvenile idiopathic arthritis (pJIA), according to findings from Ringold et al.
The ACR’s delegation to the American Medical Association’s House of Delegates is gearing up for the HOD Interim Meeting, slated for Nov. 14–18. Several members share their views on the value of this advocacy work and top issues this fall.